La chaîne d'options affiche les données clés des options sur actions de Singular Genomics Sys à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Singular Genomics Sys..

Singular Genomics Sys (NASDAQ:OMIC) Stock, Chaîne d'Options

Singular Genomics Sys

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Earnings

News

TRDA

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_05112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
EURUSD remains poised around 1.0878 as markets brace for the outcome of the highly anticipated US presidential election. With the world watching, the direction of the major currency pair will hinge significantly on the election results, where a victory for Donald Trump is likely to bolster the USD, potentially leading to a notable increase. Conversely, a win for Kamala Harris could see the USD decline by an average of 1-2%.
The impending volatility is not solely due to the election but amplified by the upcoming Federal Reserve meeting scheduled for Wednesday. The Fed is anticipated to cut interest rates slightly by 25 basis points. Market participants are keenly awaiting any forward guidance from the Fed, particularly with expectations leaning towards another rate reduction in December.
While significant economic data releases are also expected, these pivotal events may overshadow their impact.
<h3>Technical Analysis Of EUR/USD</h3>
<a href="https://www.benzinga.com/files/u117641/eurusdh4_71.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh4_71.png" style="height:280px; width:624px" /></a>
The EURUSD market has completed a growth structure reaching 1.0913, considered part of a third growth wave targeting 1.0950. After this target is achieved, a retraction to 1.0860 is anticipated, potentially forming a broad consolidation range around this level. Technical indicators, such as the MACD, suggest an upward trajectory, reinforcing the possibility of reaching 1.0960 before a corrective pullback to 1.0860.
<a href="https://www.benzinga.com/files/u117641/eurusdh1_72.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh1_72.png" style="height:280px; width:624px" /></a>
Support at 1.0872 has spurred the development of a growth impulse towards 1.0900, which is expected to be tested soon. Breaching this level could extend the growth wave towards 1.0950. The Stochastic oscillator supports this short-term forecast, indicating upward momentum with its signal line targeting the upper echelons around 80.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Technicals

Forex

Markets

Trading Ideas

General

EUR/USD Stabilises As US Presidential Election Unfolds

Leerink Partners analyst Mani Foroohar initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $17.

Price Target

Initiation

Analyst Ratings

CAMP

Leerink Partners Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $17

Health Care

NURO

NeuroMetrix Reports Q3 2024 Sales Of $0.6M Vs. $1.2M YoY, With EPS Loss Of $(0.75) Compared To ($1.66) YoY

As of month-end, the Company operated approximately 185,000 bitcoin miners in data centers for both self-mining and hosting, representing a total energized hash rate of 21.8 EH/s. &nbsp;

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Says It Earned 369 Bitcoin In October From Its Owned Fleet Of Miners Vs. 345 In September

Select October 2024 Highlights
<ul>
<li>Record total average daily volume ("ADV") of $46.2 billion increased 40% compared to the prior year, and increased 2% compared to September 2024. These strong results were driven by total credit ADV of $15.0 billion, representing an increase of 19% compared to the prior year, and a decrease of 9% compared to September 2024. Record total rates ADV of $31.2 billion, which increased 54% compared to the prior year, and increased 9% compared to September 2024 levels, also contributed to the strong performance in October 2024.</li>
<li>Record total trading volume of $1.0 trillion on the platform increased 47% compared to the prior year, and increased 12% compared to September 2024.</li>
</ul>

MKTX

MarketAxess Announced Trading Volume For October 2024 With Total Average Daily Volume Of $46.2B, Up 40% YoY And +2% Compared To September 2024

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. The company reported quarterly sales of $167.824 million which beat the analyst consensus estimate of $167.010 million by 0.49 percent. This is a 10.44 percent increase over sales of $151.954 million the same period last year.

Earnings Beats

NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate

Leerink Partners analyst Christopher Liu downgrades IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowers the price target from $41 to $27.

Downgrades

IDYA

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27

Pseudonymous crypto analysts DonAlt and CryptoCred explored Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price trends and the impact of <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re">Tuesday&#8217;s presidential election</a>.
Bitcoin's Expected Trajectory
In the latest &#8216;Technical Roundup&#8217; <a href="https://www.youtube.com/watch?v=IhonU0vEFQE&amp;pp=ygURdGVjaG5pY2FsIHJvdW5kdXA%3D">episode</a>, DonAlt noted Bitcoin's recent surge to close to its all-time high before retreating below $70,000, calling the monthly close "catastrophic" after a key resistance retest.
He projected $49,000 as the first support level in the short term, with more robust support near $35,000 on a monthly timeframe, and in an extreme scenario, a possible drop to $16,000.
DonAlt attributes recent sluggish crypto market activity to positioning ahead of a potential Trump victory. He <a href="https://x.com/CryptoDonAlt/status/1853452002983813251">cautioned</a> on X that a Trump win might bring only modest short-term upside for Bitcoin, while a loss could trigger a sell-off, with a Harris win potentially causing an even steeper decline. Emphasizing flexibility, DonAlt highlighted the need for strategic preparation as election results unfold.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a>
Ethereum's Play
DonAlt also commented on Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance relative to Bitcoin, stressing the dependency of ETH/BTC strength on Bitcoin's movement. He shared his open position in a SOL/BTC trade.
Given the election uncertainty, DonAlt concluded, "I'm not going to trade in the next weeks, maybe months," stressing the importance of caution in the current environment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41709166/bitcoin-to-hit-100-000-by-january-2025-could-black-hole-effect-push-the-largest-crypto-to-">Bitcoin To Hit $100,000 By January 2025? Could &#8216;Black Hole Effect&#8217; Push The Largest Crypto To Never-Before-Seen Levels</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Veteran Traders Share 'Presidential Election Crypto Trading Roadmap,' Predict Heavy Volatility

<a href="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona" title="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona">https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona</a>

AMZN

Amazon Says Customers In West Valley Phoenix Metro Area Now Receiving Prime Air Drone Deliveries

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) reported quarterly earnings of $0.08 per share. This is unchanged from the same period last year. The company reported $1.02 billion in sales this quarter. This is a 12.64 percent increase over sales of $909.09 million the same period last year.

CLPBY

Coloplast Q4 EPS $0.08, Same YoY, Sales $1.02B Up From $909.09M YoY

Biotech

RNAZ

Transcode Therapeutics Has Received Notice From The Nasdaq Stock Market To Grant Transcode's Request To Continue Its Listing On The Nasdaq Stock Market Subject To Certain Conditions To Regain Compliance

The Company anticipates releasing its financial results for the six months ended June 30, 2024, by the end of November.
 &nbsp;

HUBC

HUB Security Says Making Progress On All Fronts, With Steady Advancement In Existing Contracts; Aims To Strategically Position Itself For Significant Penetration Into US Market In Q1 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financials sector.
<h3 class="wp-block-heading">Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>)</h3>
<ul>
<li>Dividend Yield: 5.47%</li>
<li>Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $28 to $29 on Oct. 10. This analyst has an accuracy rate of 75%.</li>
<li>Barclays analyst Alex Scott maintained an Equal-Weight rating and raised the price target from $35 to $36 on Oct. 8. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Oct. 31, Lincoln National posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest LNC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png" alt="" class="wp-image-629784" style="width:694px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-768x704.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Heritage Commerce Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>)</h3>
<ul>
<li>Dividend Yield: 5.44%</li>
<li>Piper Sandler analyst Andrew Liesch maintained an Overweight rating and raised the price target from $10 to $12 on July 26. This analyst has an accuracy rate of 78%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay maintained an Outperform rating and increased the price target from $10.5 to $11.5 on July 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 24, Heritage Commerce posted in-line quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest HTBK news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png" alt="" class="wp-image-629786" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-768x715.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>Dividend Yield: 5.19%</li>
<li>Truist Securities analyst Brandon King maintained a Hold rating and raised the price target from $28 to $30 on Oct. 28. This analyst has an accuracy rate of 81%.</li>
<li>RBC Capital analyst Jon Arfstrom maintained a Sector Perform rating and increased the price target from $29 to $31 on Oct. 25. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Oct. 24, Columbia Banking System posted better-than-expected quarterly results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> trend in COLB stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png" alt="" class="wp-image-629787" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735699/archer-daniels-midland-yum-brands-and-3-stocks-to-watch-heading-into-tuesday">Archer-Daniels-Midland, Yum! Brands And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

Dividends

Pre-Market Outlook

COLB

HTBK

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 14.55 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $4.89 million which beat the analyst consensus estimate of $3.35 million by 46.09 percent. This is a 47.94 percent increase over sales of $3.31 million the same period last year.

STOK

Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $164 to $154.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $154

JP Morgan analyst Tessa Romero initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Overweight rating and announces Price Target of $38.

JP Morgan Initiates Coverage On Upstream Bio with Overweight Rating, Announces Price Target of $38

Guidance

VERV

Verve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026

R1 RCM Says It Is Not Providing Financial Guidance Due To Previously Announced Proposed Acquisition Of R1

2024 Outlook
Today, Sotera Health is reaffirming the following 2024 outlook ranges previously provided:
<ul>
<li>Net revenues and Adjusted EBITDA growth in the range of 4.0% to 6.0%,</li>
<li>Interest Expense in the range of $165 million to $175 million,</li>
<li>Tax rate applicable to Adjusted Net Income(3) in the range of 31.5% to 34.5%,</li>
<li>Adjusted EPS in the range of $0.67 to $0.75,</li>
<li>A weighted-average fully diluted share count in the range of 283 million to 285 million shares, and</li>
</ul>
The following range in the 2024 outlook is being updated:
<ul>
<li>Capital expenditures are now expected to be in the range of $175 million to $185 million, from previous guidance of $205 million to $225 million</li>
</ul>

Sotera Health Co Reaffirmed Its 2024 Guidance Of Net Revenue Growth Of 4%-6%; Adj. EPS Of $0.67-$0.75 Vs. $0.72 Est.; Sees Capital Expenditures Of $175M-$185M (Priro $205M-$225M)

Singular Genomics announces 1-for-30 reverse stock split

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Singular Genomics Sys (NASDAQ:<a href="https://investorplace.com/stock-quotes/omic-stock-quote/">OMIC</a>) just reported results for the second quarter of 2023.<ul><li>Singular Genomics Sys reported earnings per share of -$10.50. This was above the analyst estimate for EPS of -$11.10.</li><li>The company reported revenue of $505,000.</li><li>This was 56.09% worse than the analyst estimate for revenue of $1.15 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/omic-stock-earnings-singular-genomics-sys-for-q2-of-2023/">OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Misses Revenue for Q2 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Misses Revenue for Q2 2023

Singular Genomics regains compliance with Nasdaq

Singular Genomics Systems GAAP EPS of -$8.57 beats by $0.29, revenue of $0.7M beats by $0.29M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Singular Genomics Sys (NASDAQ:<a href="https://investorplace.com/stock-quotes/omic-stock-quote/">OMIC</a>) just reported results for the second quarter of 2024.<ul><li>Singular Genomics Sys reported earnings per share of -$8.57. This was above the analyst estimate for EPS of -$8.88.</li><li>The company reported revenue of $737,000.</li><li>This was 84.25% better than the analyst estimate for revenue of $400,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/omic-stock-earnings-singular-genomics-sys-for-q2-of-2024/">OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Beats Revenue for Q2 2024

Singular Genomics Systems, Inc. 2024 Q2 - Results - Earnings Call Presentation

Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript

Singular Genomics receives acquisition proposal from Deerfield

Singular Genomics jumps after Tang's Concentra offers $12 a share

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

AXNX

BATL

BLCO

BOOM

CACI

FLUT

INFN

MMSI

OMIC

PLTK

PYTCY

RVNC

SATS

SMAR

STZHF

VVPR

Press Releases

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

Singular Genomics to Report First Quarter 2024 Financial Results on May 14, 2024

Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

Singular Genomics Announces 1-for-30 Reverse Stock Split

Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield

Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital

Comments

Singular Genomics Sys

Singular Genomics Sys (OMIC) Options

Singular Genomics Sys (NASDAQ:OMIC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL